[Experience with sisomicin in pediatrics (author's transl)]

Area of Science:

• Pharmacology
• Microbiology
• Pediatrics

Context:

• Aminoglycoside antibiotics are crucial for treating bacterial infections.
• Sisomicin exhibits broad-spectrum activity against Gram-negative and Gram-positive bacteria.
• Understanding sisomicin's pharmacokinetics and efficacy in pediatric populations is essential for optimizing treatment.

Purpose:

• To evaluate the efficacy and safety of sisomicin in treating various infections in pediatric patients, especially neonates and premature infants.
• To determine appropriate dosing regimens for sisomicin in different pediatric age groups based on pharmacokinetic data.
• To assess the incidence and nature of side effects associated with sisomicin treatment in children.

Summary:

• Sisomicin, an aminoglycoside antibiotic, is effective against a range of bacteria including Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.
• Pharmacokinetic studies indicate specific dosage requirements for neonates, infants, and school-aged children.
• Clinical data from 58 patients, predominantly neonates and prematures, show an 85% success rate in treating diverse infections with minimal, transient side effects.

Impact:

• Sisomicin offers a viable treatment option for serious bacterial infections in pediatric patients, including neonates.
• The study provides evidence-based dosing guidelines for sisomicin in children, aiding clinicians in effective drug utilization.
• The favorable safety profile suggests sisomicin can be safely administered to vulnerable pediatric populations with careful monitoring.